PGF and melanoma: In particular, D16F7 mAb: (a) disrupts the interaction of α5β1 integrin expressed in melanoma cells with the sVEGFR-1 deposited on the ECM by the tumor and vascular endothelium, interaction that favors cell motility through the matrix toward surrounding tissues; (b) blocks the ability of melanoma cells to enter into the bloodstream across the endothelial layer; and (c) downmodulates PlGF production.